Nerdwallet Inc vs Smith & Nephew plc — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $616.22M), while Smith & Nephew plc trades at $30.08 (market cap $12.38B). The key difference: Smith & Nephew plc is far larger — about 20.1× Nerdwallet Inc's market cap, and Smith & Nephew plc pays a 2.66% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | SNN | |
|---|---|---|
Market Cap | $616.22M | $12.38B |
Sector | Financials | Health |
52-Week High | $15.93 | $38.70 |
52-Week Low | $7.58 | $28.73 |
Enterprise Value | $530.52M | $15.41B |
Dividend Yield | — | 2.66% |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.
NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Trailing returns across standard periods
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →